Table 2

Clinical symptoms of mixed connective tissue disease patients with and without cardiovascular diseases

MCTD manifestation

MCTD (n = 50)

MCTD/CVD+ (n = 23)

MCTD/CVD- (n = 27)

P valuea, CVD+ vs. CVD-


Disease duration (years)

9.56 ± 6.8 (3 to 26)

10.3 ± 6.6 (3 to 26)

8.9 ± 6.9 (3 to 25)

0.481

Polyarthritis

46 (92)

22 (95.6)

24 (88.8)

0.6123

Raynaud's phenomenon

39 (78)

22 (95.6)

17 (62.9)

0.006

Myositis

30 (60)

13 (56.5)

17 (62.9)

0.8621

Interstitial lung disease

40 (80)

19 (82.6)

21 (77.7)

0.7356

Photosensitivity

12 (24)

7 (30.4)

5 (18.5)

0.5077

Esophageal dysmotility

35 (70)

15 (65.2)

20 (74.0)

0.5480

Pulmonary arterial hypertension

12 (24)

9 (39.1)

3 (11.1)

0.0141

Lymphadenomegaly

13 (0.26)

5 (21.7)

8 (29.6)

0.7474

Serositis

19 (38)

11 (47.8)

8 (29.6)

0.2465

Secondary antiphospholipid syndrome

15 (30)

11 (47.8)

4 (14.8)

0.015

Previous venous thrombosis

13 (26.0)

9 (39.1)

4 (14.8)

0.618

Previous arterial occlusion

2 (4.0)

2 (8.69)

0

Anti-U1RNP (normal: <10 U/ml)

50 (100)

23 (100)

27 (100)

Anti-CL IgG/IgM (normal: <10 U/ml)

19 (38)

13 (56)

6 (22)

0.0195

AECA (normal: <5 U/ml)

22 (44)

15 (65)

7 (26)

0.001

SLAM (median)

5

5

4

SLAM (mean ± SD)

6.28 ± 4.04

6.95 ± 4.08

5.44 ± 4.0

0.199

SLAM (n)

18 (36)

11 (47.8)

7 (25.9)

0.1438

Medication

Nonsteroidal anti-inflammatory drugs

22 (44)

10 (43.4)

12 (44.4)

1.0

Last 2 months average dose of corticosteroids (mg/day)

3.36 ± 4.8

4.1 ± 3.4

3.1 ± 5.2

0.5306

Cumulative lifetime dose (prednisone equivalent)

14.21 (4 to 58.965)

13.0 (4 to 59.432)

15.2 (4 to 57.437)

0.674

Corticosteroids alone or combination (n)

28 (56)

11 (47.8)

17 (62.9)

0.3926

Patients currently corticosteroids alone n (%)

7 (14)

2 (8.6)

5 (18.5)

0.4295

Patients currently corticosteroids plus salazopyrine

10 (20)

5 (21.7)

5 (18.5)

1.0

Patients currently corticosteroids plus methotrexate

11 (22)

5 (21.7)

6 (22.2)

1.00

Cyclophosphamide treatment ever

37 (74)

21 (91.3)

16 (59.2)

0.0119

Antimalaric drugs treatment ever

39 (78)

19 (82.6)

20 (74.0)

0.515

Cyclosporin-A treatment ever

10 (20)

7 (30.4)

3 (11.1)

0.4804


Data presented as mean ± standard deviation, n (%) or median (25th to 75th percentile). AECA, anti-endothelial cell antibody; anti-CL, anti-cardiolipin; anti-U1RNP, anti-U1 ribonucleoprotein; CVD, cardiovascular disease; MCTD, mixed connective tissue disease. The systemic lupus erythematosus disease activity measure (SLAM) is a measure of disease activity [24,25]. aFischer's exact test and Student t test.

Soltesz et al. Arthritis Research & Therapy 2010 12:R78   doi:10.1186/ar2999

Open Data